#NICE #JnJ #Haematology #multiplemyeloma #daratumumab #daratumumabquadruplet #transplanteligiblemyeloma #NICEGuidance #MRDguidedtreatment #NICEFinalDraftGuidance #PERSEUSdata #daratumumabbasedregimen #VRdinduction #MRDguidedapproach #personalisedtreatment #PatientAccess
zurl.co/ZmXyU
zurl.co/ZmXyU
NICE backs daratumumab quadruplet for transplant‑eligible myeloma - PharmaTimes
Guidance supports MRD‑guided treatment approach
pharmatimes.com
September 21, 2026 at 8:54 AM
#NICE #oncology #recurrentcervicalcancer #metastaticcervicalcancer #NHS #cervicalcancer #NICEfinaldraftguidance #cemiplimab #Libtayo #Regeneron #immunotherapy #overallsurvival #medicinesevaluation #Clinicaltrialdata #EMPOWERCervical1study #CancerDrugsFund #NHScommissioning
zurl.co/6UaVw
zurl.co/6UaVw
New treatment option recommended for recurrent or metastatic cervical cancer
www.nice.org.uk
June 26, 2026 at 11:19 AM
#gastro #immunology #gastroenterology #mirikizumab #Omvoh #EliLilly #Crohnsdisease #Crohnsdiseasetreatment #NICE #NICEfinaldraftguidance #MHRA #marketingauthorisation #VIVID1clinicaltrial #clinicalremission #inflammatoryboweldisease #CrohnsandColitisUK
pharmatimes.com/news/nice-re...
pharmatimes.com/news/nice-re...
NICE recommends mirikizumab for Crohn's disease treatment - PharmaTimes
New guidance expands treatment options for eligible patients
pharmatimes.com
June 3, 2025 at 9:47 AM
#Haematology #NICE #JnJ #daratumumabquadruplet #newlydiagnosedtransplantineligiblemyeloma #multiplemyeloma #autologousstemcelltransplant #NICEFinaldraftguidance #DVRd #NHS #subcutaneousCD38directedantibodyquadruplet #MyelomaUK #CEPHEUStrial #transplantineligiblemyelomapatients
zurl.co/Nf61Q
zurl.co/Nf61Q
NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma - PharmaTimes
Final draft guidance recommends D‑VRd on the NHS in England and Wales
pharmatimes.com
June 12, 2026 at 10:20 AM
#Cervicalcancer #NICE #Genmab #Oncology #Tivdak #NHS #reimbursement #NICEfinaldraftguidance #NHScommissioning #recurrentcervicalcancer #metastaticcervicalcancer #MHRA #innovaTV301trial #RoyalMarsden #tissuefactortargetingantibodydrugconjugate #ADCs #CancerDrugsFund #CDF
zurl.co/5j6Ol
zurl.co/5j6Ol
NICE changes stance on Genmab's cervical cancer drug
After saying it couldn't recommend Genmab's cervical cancer therapy Tivdak for use by the NHS, reimbursement authority NICE has had a change of heart.
pharmaphorum.com
May 28, 2026 at 9:20 AM
#breastcancer #NICE #NHS #HEOR #Enhertu #AstraZeneca #DaiichiSankyo #Oncology #HER2lowbreastcancer #incurablebreastcancer #NICEFinaldraftguidance #reimbursement #metastaticbreastcancer #NICEcosteffectivenessthreshold #NICErecommendation #CancerDrugsFund #NHScommissioning
zurl.co/eYPtT
zurl.co/eYPtT
NICE finally backs Enhertu for HER2-low breast cancer
Almost three years after Enhertu was made available in Scotland, the drug is finally an option for patients in England with HER2-low breast cancer.
pharmaphorum.com
September 18, 2026 at 8:24 AM
#Merck #Ezmekly #NHSuse #HEOR #MarketAccess #MerckKGaA #Neurofibromatosis #NF1 #NFItherapy #rarediseases #Reimbursement #NICE #oralMEKinhibitor #plexiformneurofibromas #PN #PNassociatedwithNF1 #paediatrics #MHRA #NICEfinaldraftguidance #paediatricNF1patients
#Merck #Ezmekly #NHSuse #HEOR #MarketAccess #MerckKGaA #Neurofibromatosis #NF1 #NFItherapy #rarediseases #Reimbursement #NICE #oralMEKinhibitor #plexiformneurofibromas #PN #PNassociatedwithNF1 #paediatrics #MHRA #NICEfinaldraftguidance #paediatricNF1patients
News update via NF Bot
bsky.app
September 7, 2026 at 12:33 PM
#Merck #Ezmekly #NHSuse #HEOR #MarketAccess #MerckKGaA #Neurofibromatosis #NF1 #NFItherapy #rarediseases #Reimbursement #NICE #oralMEKinhibitor #plexiformneurofibromas #PN #PNassociatedwithNF1 #paediatrics #MHRA #NICEfinaldraftguidance #paediatricNF1patients
#Merck #Ezmekly #NHSuse #HEOR #MarketAccess #MerckKGaA #Neurofibromatosis #NF1 #NFItherapy #rarediseases #Reimbursement #NICE #oralMEKinhibitor #plexiformneurofibromas #PN #PNassociatedwithNF1 #paediatrics #MHRA #NICEfinaldraftguidance #paediatricNF1patients #ReNeutrial #PNlesions
zurl.co/8MUea
zurl.co/8MUea
Merck rare tumour drug Ezmekly backed for NHS use
Merck's drug for tumours associated with rare disease neurofibromatosis type 1, Ezmekly, has been cleared for NHS use in children as young as two.
pharmaphorum.com
September 7, 2026 at 12:13 PM
#Bayer #Kerendia #finerenone #NICE #cardiovasculardiseases #chronicheartfailure #CHF #NICEFinaldraftguidance #symptomaticCHF #heartfailurewithmildlyreducedejectionfraction #HFmrEF #heartfailurewithpreservedejectionfraction #HFpEF #MHRA #FINEARTSHFstudy #cardiovascularoutcomes
zurl.co/sk420
zurl.co/sk420
Bayer's Kerendia on course for NHS use in heart failure
Up to 280,000 people with heart failure could soon be eligible for NHS treatment with Bayer's Kerendia, following new NICE guidance.
pharmaphorum.com
July 20, 2026 at 9:22 AM
#NICE #NHSfunding #Amgen #lungcancer #lungcancerpatients #Lumykras #sotorasib #CancerDrugsFund #CDF #healthtechnologyassessment #HTA #KRASinhibitor #England #Wales #nonsmallcelllungcancer #NSCLC #NICEfinaldraftguidance #NHScommissioning #costeffectiveness #KRASG12Cmutations
zurl.co/8C57B
zurl.co/8C57B
NICE aims to cut funding for Amgen lung cancer drug Lumykras
Amgen's Lumykras will no longer be funded by the Cancer Drugs Fund for KRAS-mutated lung cancer, says NHS reimbursement authority NICE.
pharmaphorum.com
July 13, 2026 at 11:06 AM
#NHS #ITF #Duchennedrug #ITFPharma #Duchennemusculardystrophy #DMD #Duvyzat #givinostat #NHSpatients #England #NICEFinaldraftguidance #reimbursement #oralHDACinhibitor #InnovativeMedicinesFund #IMF #NHSEngland #routineNHSfunding #NICEcosteffectivenessthreshold #phase3 #EPIDYSstudy
zurl.co/LRmEl
zurl.co/LRmEl
Deal finally unlocks NHS access to ITF's Duchenne drug
After nearly two years of wrangling, ITF's Duvyzat can be used by the NHS to treat people living with Duchenne muscular dystrophy.
zurl.co
May 11, 2026 at 12:52 PM
#Keytruda #pembrolizumab #immunotherapy #headandneckcancer #PharmaNews #MSD #NICE #reimbursement #NICEfinaldraftguidance #NHSEngland #headandnecksquamouscellcarcinoma #HNSCC #LAHNSCC #PDL1biomarker #PD1inhibitor #KEYNOTE689trial #perioperativeimmunotherapy #PDL1positiveHNSCC
zurl.co/y2cQh
zurl.co/y2cQh
Keytruda cleared for NHS use in early head and neck cancer
MSD's Keytruda is poised to end a 20-year drought in new advances in NHS treatment for early-stage head and neck cancer
zurl.co
March 25, 2026 at 10:16 AM
#COPDpatients #Dupixent #dupilumab #NHS #chronicobstructivepulmonarydisease #COPD #biologics #Sanofi #Regeneron #uncontrolledCOPD #lungdisease #COPDtherapies #NICEfinaldraftguidance #COPDflareups #COPDdiagnosis #NICE #NHScostsavings #uncontrolledCOPD #COPDcare
zurl.co/7i5io
zurl.co/7i5io
COPD patients will get access to Dupixent via NHS
Almost 30,000 people in England with COPD stand to get access to Dupixent, the first biologic for the devastating disease, after NICE backs its use.
pharmaphorum.com
January 29, 2026 at 12:34 PM
#haematology #NICE #NHS #leukaemiaCART #Autolus #leukaemia #CARTtherapy #NHSroutinecommissioning #Aucatzyl #BcellALL #acutelymphoblasticleukaemia #relapsedALL #refractoryALL #Bcellprecursoracutelymphoblasticleukaemia #ALL #NICEfinaldraftguidance #HTA #FELIXtrial #NICEguidance
zurl.co/h6OwD
zurl.co/h6OwD
NICE backs NHS use of Autolus' leukaemia CAR-T
Hundreds of people with an aggressive leukaemia will be able to access a CAR-T therapy developed by UK biotech Autolus after a NICE recommendation.
pharmaphorum.com
December 4, 2025 at 9:39 AM
#AlnylamUK #NICE #vutrisiran #Amvuttra #ATTRCM #NICEfinaldraftguidance #transthyretinamyloidosiswithcardiomyopathy #hereditaryATTR #stage1polyneuropathy #stage2polyneuropathy #NICEfinalguidance #HELIOSBstudy #cardiovascular #stiffheartdisease #AnnaTomlinson #CardiomyopathyUK
zurl.co/0yB9A
zurl.co/0yB9A
NICE recommends vutrisiran for adults with ATTR-CM in final draft guidance - PharmaTimes
First long-acting therapy with three-monthly dosing to target root cause of cardiac disease
pharmatimes.com
November 26, 2025 at 1:02 PM
#Ophthalmology #eyedisease #LHON #Lebershereditaryopticneuropathy #mitochondrialgeneticdisorder #Chiesi #Raxone #idebenone #NICE #NICEfinaldraftguidance #centralvisionloss #visionloss #LHONgenes #LHONSociety #mitochondrialDNA #mtDNA #RHODOStrial #LEROStrail #PAROStrial
zurl.co/W87n3
zurl.co/W87n3
England poised to roll out drug for rare eye disease LHON
Patients in England with rare eye disorder LHON will finally get access to a Chiesi drug that has been available in the rest of the UK for years.
zurl.co
August 8, 2025 at 9:41 AM
#womenshealth #oncology #NICE #NICErecommended #MerckSharpandDohme #MSD #immunotherapy #endometrialcancer #advancedwombcancer #wombcancer #pembrolizumab #Keytruda #NICEfinaldraftguidance #gynaecologicalcancer #UK #stage4tendometrialcancer #CancerDrugsFund
www.nice.org.uk/news/article...
www.nice.org.uk/news/article...
NICE approves first immunotherapy combination for endometrial cancer
NICE approves first immunotherapy combination for endometrial cancer
www.nice.org.uk
August 7, 2025 at 8:39 AM
#NICE #oncology #breastcancer #breastcancerpatients #NHStreatment #NICEapproved #ribociclib #Kisqali #Novartis #earlystagebreastcancer #NICEfinaldraftguidance #aromataseinhibitor #hormonereceptorpositiveHER2negativeearlybreastcancer #Milestoneforbreastcancercare
www.nice.org.uk/news/article...
www.nice.org.uk/news/article...
Thousands more breast cancer patients to benefit from new NHS treatment
www.nice.org.uk
July 23, 2025 at 8:27 AM
#NICE #betulaverrucosa #Itulazax12SQBet #AlkAbelló #immunotherapy #severebirchtreepollenallergy #birchtreepollenallergy #NICErecommended #underthetonguetabletimmunotherapy #allergens #NICEfinaldraftguidance #treepollen #allergens #treepollenallergies #treepollen
www.nice.org.uk/news/article...
www.nice.org.uk/news/article...
Thousands could benefit from first immunotherapy for severe birch tree pollen allergy
First immunotherapy for severe birch tree pollen allergy recommended by NICE
www.nice.org.uk
July 22, 2025 at 2:01 PM
#NICE #NICEFAD #NICEfinaldraftguidance #Alzheimerstreatments #NHS #donanemab #Kisunla #EliLilly #lecanemab #Leqembi #Eisai #negativedraftrecommendations #mildcognitiveimpairment #milddementia #Alzheimersdisease #NHSresources #NICEassessments #cognitiveimpairment
www.nice.org.uk/news/article...
www.nice.org.uk/news/article...
Final draft guidance finds benefits of 2 Alzheimer’s treatments remain too small to justify the additional costs to the NHS
The benefits of Alzheimer’s treatments donanemab and lecanemab remain too small to justify the additional costs
www.nice.org.uk
June 19, 2025 at 10:47 AM
#womenshealth #endometriosis #symptomsofendometriosis #NICEfinaldraftguidance #NICErecommended #NICEguidance #Linzagolix #Yselty #Theramex #endometriosissymptoms #NHSservices #medicinesevaluation #fasttrackevaluation #patientaccess #NHSinEngland
www.nice.org.uk/news/article...
www.nice.org.uk/news/article...
Up to 1,000 women a year could benefit from new at-home treatment for endometriosis
www.nice.org.uk
May 9, 2025 at 9:01 AM